Akari Therapeutics (AKTX) Gains from Investment Securities (2015 - 2026)

Akari Therapeutics has disclosed Gains from Investment Securities across 12 years of filings, most recently posting $8750.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $8750.0, down 98.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $8750.0 (down 98.91% YoY), and the FY2025 annual result was $170137.0, down 97.23% from the prior year.
• Gains from Investment Securities came in at $8750.0 for Q1 2026 at Akari Therapeutics, down from $170137.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $19.2 billion in Q2 2025 to a low of -$120.5 million in Q2 2024.
• The 5-year median for Gains from Investment Securities is $1.4 million (2023), against an average of $1.8 billion.
• Across the five-year window, Gains from Investment Securities tumbled 114.08% in 2024 and jumped 50068.51% in 2025, its largest moves.
• Akari Therapeutics' Gains from Investment Securities stood at $513.7 million in 2022, then tumbled by 99.61% to $2.0 million in 2023, then surged by 209.84% to $6.1 million in 2024, then sank by 97.23% to $170137.0 in 2025, then tumbled by 94.86% to $8750.0 in 2026.
• The last three Gains from Investment Securities figures came in at $8750.0 (Q1 2026), $170137.0 (Q4 2025), and $587130.0 (Q3 2025), per Business Quant data.